Global Drug-Eluting Stents Market Size study & Forecast, by Coating (Polymer Based, Polymer Free), By Application (Coronary Artery Disease, Peripheral Artery Disease), By End-User (Hospitals, Ambulatory Surgical Centers, Others) and Regional Analysis, 202

Global Drug-Eluting Stents Market Size study & Forecast, by Coating (Polymer Based, Polymer Free), By Application (Coronary Artery Disease, Peripheral Artery Disease), By End-User (Hospitals, Ambulatory Surgical Centers, Others) and Regional Analysis, 2023-2030

Global Drug-Eluting Stents Market is valued at approximately USD 7.37 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.6% over the forecast period 2023-2030. Drug-eluting stents are medical devices used in interventional cardiology to treat narrowed or blocked arteries; a condition known as coronary artery disease. They are tiny metal tubes, usually made of stainless steel or cobalt-chromium alloy, that are coated with a special medication designed to prevent the formation of scar tissue inside the artery and keep it open for blood flow. The Drug-Eluting Stents market is expanding because of factors such as increasing prevalence of cardiovascular disease and rise in geriatric population. The development of DES has revolutionized the treatment of coronary artery disease by reducing the risk of re-narrowing the artery, known as restenosis, which was a common problem with bare-metal stents. Its prevalence has progressively increased during the last few decades.

According to the American Heart Association, Cardiovascular disease remains the leading cause of death in the United States, accounting for 928,741 deaths in the year 2020. Furthermore, in 2020 in the United States, coronary heart disease was the leading cause of death around 41.2% attributable to CVD in the United States, followed by stroke at 17.3%, and other cardiovascular diseases at 16.8%. Another important component driving space is rise in geriatric population. As geriatric and obese populations are predisposed to chronic diseases. According to the World Bank Group, the world’s old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. In addition, in May 2022, Biosensors International Group launched BioFreedom Ultra. It is a new polymer and carrier-free drug-coated stent using Biosensors' patented limus medication Biolimus A9. It is a highly lipophilic anti-restenotic medication developed by Biosensors intended for coronary vascular applications. BioFreedom Ultra additionally includes 84m thin Cobalt Chromium (Co/Cr) struts. Also, advancements in the formulation of drug-eluting stents and increasing demand for biodegradable polymer-based drug eluting scaffolds would create a lucrative growth prospectus for the market over the forecast period. However, the high cost of Drug-Eluting Stents stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Drug-Eluting Stents Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players and rising technological advancement in health examination devices. According to Statista, in 2021, the number of cardiovascular surgeries in North America accounts for 202907 Coronary Artery Bypass Graft Procedures, and 258139 Isolated Valve Procedures. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric populations, and active participation of government organizations in the market space.

Major market players included in this report are:
Boston Scientific Corporation,
Medtronic plc
Abbott Laboratories,
Biosensors International Group,
AlviMedica Medical Technologies Inc.,
Amaranth Medical, Inc.,
HangZhou HuaAn Biotechnology Co., Ltd,
XTENT, Inc.,
Cardionovum GmbH,
Kyoto Medical Planning Co., Ltd.

Recent Developments in the Market:
In February 2023, Medtronic plc acquired the CE Mark for the Aurora EV-ICDTM MRI SureScanTM and Epsila EVTM MRI SureScanTM defibrillation leads for the treatment of extremely fast heartbeats that can lead to sudden cardiac arrest. Because its lead (thin wire) is located outside the heart and veins, the Aurora EV-ICD system provides the life-saving benefits of regular ICDs while avoiding certain hazards.

Global Drug-Eluting Stents Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Coating, Application, End-User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Coating
Polymer Based
Polymer Free

By Application
Coronary Artery Disease
Peripheral Artery Disease

By End-User
Hospitals
Ambulatory Surgical Centers
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Boston Scientific Corporation,
Medtronic plc
Abbott Laboratories,
Biosensors International Group,
AlviMedica Medical Technologies Inc.,
Amaranth Medical, Inc.,
HangZhou HuaAn Biotechnology Co., Ltd,
XTENT, Inc.,
Cardionovum GmbH,
Kyoto Medical Planning Co., Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.